Spotlight on Genting Berhad in this week’s Corporate Profile by Trushna.
Report from RHB Research (3 March 2016) include link to the prospect of IPO of the pharmaceutical unit of Genting Berhad. With good Phase 3 result of experimental Alzheimer’s drug coming in July, the indicative IPO value is said to be USD$15 billion. How will this affect the share price of Genting Berhad?
Watch this video to find out more.